Gossamer Bio Analysts Lower Forecasts Amid Regulatory Uncertainty

Analysts have revised forecasts for Gossamer Bio (GOSS) amid an uncertain regulatory environment. The company's primary therapy, seralutinib, is being developed for pulmonary arterial hypertension. H.C. Wainwright & Co. lowered its price target from $10 to $5, while Oppenheimer & Co. reiterated its "Outperform" rating with a new price target of $3. Despite the revisions, Gossamer Bio has support from 44% of analysts who maintain a "Buy" rating, with a consensus price target of $1.00 indicating an upside potential of 117.39%.